Breaking down the barrier: The effects of HIV-1 on the blood–brain barrier

详细信息    查看全文

• 作者：Marianne Strazza^a ; Vanessa Pirrone^a ; Brian Wigdahl^a ; Michael R. Nonnemacher ; ^a ; ^{monnema@drexelmed.edu"" rel=""nofollow} ;
• 关键词：HIV ; Blood– ; brain barrier ; Tat ; Nef ; gp120 ; Drugs of abuse
• 刊名：Brain Research
• 出版年：2011
• 出版时间：5 July 2011
• 年：2011
• 卷：1399
• 期：Complete
• 页码：96-115
• 全文大小：1815 K

文摘

Human immunodeficiency virus type 1 (HIV-1) primarily infects CD4⁺ T cells and cells of the monocyte–macrophage lineage, resulting in immunodeficiency in an infected patient. Along with this immune deficiency, HIV-1 has been linked to a number of neurological symptoms in the absence of opportunistic infections or other co-morbidities, suggesting that HIV-1 is able to cross the blood–brain barrier (BBB), enter the central nervous system (CNS), and cause neurocognitive impairment. HIV-1-infected monocyte–macrophages traverse the BBB and enter the CNS throughout the course of HIV-1 disease. Once in the brain, both free virus and virus-infected cells are able to infect neighboring resident microglia and astrocytes and possibly other cell types. HIV-1-infected cells in both the periphery and the CNS give rise to elevated levels of viral proteins, including gp120, Tat, and Nef, and of host inflammatory mediators such as cytokines and chemokines. It has been shown that the viral proteins may act alone or in concert with host cytokines and chemokines, affecting the integrity of the BBB. The pathological end point of these interactions may facilitate a positive feedback loop resulting in increased penetration of HIV into the CNS. It is proposed in this review that the dysregulation of the BBB during and after neuroinvasion is a critical component of the neuropathogenic process and that dysregulation of this protective barrier is caused by a combination of viral and host factors including secreted viral proteins, components of the inflammatory process, the aging process, therapeutics, and drug or alcohol abuse.